Safety Study of Use of Autologous Bone Marrow Derived Stem Cell in Treatment of Age Related Macular Degeneration

Intravitreal Injection of Human Bone Marrow Derived Mesenchymal Stem Cell in Patients With Dry Age-related Macular Degeneration(AMD)

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02016508

Enrollment

Registered

2013-12-20

Start date

2013-03-31

Completion date

2015-06-30

Last updated

2013-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age Related Macular Degeneration

Keywords

Adult bone marrow stem cells, AMD

Brief summary

The purpose of this Phase I/II study is to investigate the safety and preliminary efficacy of unilateral intravitreally transplantation of adult bone marrow stem cells in subjects with geographic atrophy secondary to age-related macular degeneration.

Detailed description

This study is an open-label investigation of the safety and preliminary efficacy of unilateral intravitreal injection of autologous bone marrow stem cells in subjects with Geographic Atrophy secondary to Age-Related Macular Degeneration (AMD). Subjects will be enrolled based on specific inclusion/exclusion criteria and evaluated at regular post transplant intervals. Human central nervous system -stem cells will be transplanted by a vitreoretinal surgeon. The transplantation will be conducted in the eye with the inferior best-corrected visual acuity (BCVA) (i.e., the Study Eye). Only the Study Eye will undergo transplantation. The adult bone marrow stem cells will be administered into the vitreous cavity through a standard surgical approach. Moxifloxacin 300 mg(once per day ) will be administered orally to all subjects for a period of five days ( 2 days pre and post operatively) . Subjects will be monitored frequently for a total of one year after adult bone marrow stem cells cell injection .

Interventions

DRUGautologous bone marrow derived stem cells

intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of age-related macular degeneration with geographic atrophy (GA) * Only patients with a specific degree and extent of GA will be eligible * Subjects with best-corrected visual acuity (BCVA) of less than or equal to 20/400 in the Study Eye * No prior or current choroidal neovascularization in either eye * Able to provide written informed consent prior to any study related procedures * Agree to comply in good faith with all conditions of the study and to attend all required study visits

Exclusion criteria

* Prior vitreal or retinal surgery in the previous 6 months * Glaucoma * Atrophic macular disease of any other cause * Diabetic retinopathy or diabetic macular edema in either eye * Previous organ, tissue or bone marrow transplantation * Autoimmune disease * Allergy to moxifloxacin * Current or prior malignancy (or is on chemotherapy)

Design outcomes

Primary

Measure	Time frame	Description
number of subjects with adverse events	6 months	Descriptive analysis of frequency and types of adverse events experienced by each subject during the study period

Secondary

Measure	Time frame	Description
Assessment of visual function changes from the base line	6 months	assessment will include Change in the mean of BCVA, Optical Coherence Tomography imaging, fluorescein angiography, slitlamp examination with fundus photography, Electroretinographic evidence (mfERG) showing enhanced activity in the location

Countries

Egypt

Contacts

Primary ContactAbdelhakim mohamed safwat, M.D.

abdelhakimsafwat@gmail.com+201005151919

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026